|

Nilotinib Clinical Trials

5 actively recruiting trials across 3 locations

Also known as: AMN107, TASIGNA, Tasigna

Pipeline

Phase 2: 3Phase 4: 1Phase 1/2: 1

Top Sponsors

  • The Netherlands Cancer Institute1
  • Novartis Pharmaceuticals1
  • Medical College of Wisconsin1
  • Kartos Therapeutics, Inc.1
  • Gruppo Italiano Malattie EMatologiche dell'Adulto1

Indications

  • Cancer5
  • Chronic Myeloid Leukemia2
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive1
  • Neoplasia1
  • Tumors1

Other2 trials

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2

Birmingham, Alabama1 trial

KRT-232 and TKI Study in Chronic Myeloid Leukemia

University of Alabama Birmingham

Phase 1/2

Ann Arbor, Michigan1 trial

Asciminib Roll-over Study

Michigan Med University of Michigan

Phase 4

Detroit, Michigan1 trial

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

The Barbara Ann Karmanos Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.